Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

SOX17, β-catenin and CyclinD1 expression in the endometrioid adenocarcinoma and influence of 5-AZA on expression

Abstract

The present study discusses the expression and effect of the SOX17 gene in endometrioid adenocarcinoma. MTT assay is performed to determine the growth inhibition ratio of the DNA methyltransferase inhibitor 5-AZA for endometrial carcinoma cells, and the real-time fluorescence quantification PCR (qRT-PCR) was used to detect the mRNA expression of SOX17, β-catenin, and CyclinD1 in endometrial carcinoma tissues before and after using 5-AZA to treat the endometrial carcinoma cell line. There were 30 cases on endometrioid adenocarcinoma tissues and 10 cases on normal endometrial tissues. The results revealed that the expression of SOX17 in endometrioid adenocarcinoma tissues was downregulated (P < 0.05), the expression of β-catenin and CyclinD1 was upregulated (P < 0.05), and the expression of SOX17, CyclinD1, and β-catenin was negatively correlated (r = −0.353, P > 0.05; R = −0.463, P < 0.05). The higher the histological grade and FIGO staging were, the lower the expression level of SOX17 was (P < 0.05). After HEC1A cells were treated by 5-AZA, the cell growth inhibition was most obvious (IC50 = 12.033) at 72 h, as determined by MTT assay. After cell treatment by 5-AZA, the genetic expression of SOX17 significantly increased, when compared with that before treatment (P < 0.05), while the genetic expression of β-catenin and CyclinD1 significantly declined (P < 0.05). These results indicate that the expression level of SOX17 in endometrioid adenocarcinoma declined, and the upregulated expression level of SOX17 in cells inhibited the growth of tumor cells.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Obermair A, Youlden DR, Young JP, Lindor NM, Baron JA, Newcomb P, et al. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer. 2010;127:2678–84.

    Article  CAS  Google Scholar 

  2. Dinkelspiel HE, Wright JD, Lewin SN, Herzog TJ. Contemporary clinical management of endometrial cancer. Obstet Gynecol Int. 2013;2013:583891.

    Article  Google Scholar 

  3. Van den Bosch T, Coosemans A, Morina M, Timmerman D, Amant F. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26:257–66.

    Article  Google Scholar 

  4. Zhou F, Huo J, Liu Y, Liu H, Liu G, Chen Y, et al. Elevated glucose levels impair the WNT/β-catenin pathway via the activation of the hexosamine biosynthesis pathway in endometrial cancer. J Steroid Biochem Mol Biol. 2016;159:16–25.

    Article  Google Scholar 

  5. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2015. 2015;65:5–29.

    Article  Google Scholar 

  6. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012;13:e353–61.

    Article  Google Scholar 

  7. Howe LR, Brown AM. Wnt signaling and breast cancer. Cancer Biol Ther. 2004;3:36–41.

    Article  CAS  Google Scholar 

  8. Jia Y, Yang Y, Brock MV, Zhan Q, Herman JG, Guo M. Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer. J Pathol. 2013;230:194–204.

    Article  CAS  Google Scholar 

  9. Fu D, Ren C, Tan H, Wei J, Zhu Y, He C, et al. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer. Medicine (Baltim). 2015;94:e637.

    Article  CAS  Google Scholar 

  10. Yin D, Jia Y, Yu Y, Brock MV, Herman JG, Han C, et al. SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer. Discov Med. 2012;14:33–40.

    PubMed  PubMed Central  Google Scholar 

  11. Ye YW, Wu JH, Wang CM, Zhou Y, Du CY, Zheng BQ, et al. Sox17 regulates proliferation and cell cycle during gastric cancer progression. Cancer Lett. 2011;307:124–31.

    Article  CAS  Google Scholar 

  12. Liao YM, Shi Y, Ren XS, Wang WL, Gu XL, Song Y. Methylation status and expression of SOX17 gene in endometrioid carcinoma tissues. Minerva Biotecnol. 2017;29:139–44.

    Google Scholar 

  13. Christman JK. 5-Azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21(Aug):5483–9.

    Article  CAS  Google Scholar 

  14. Zhou GY, Gao P. The derivative of molecular pathology—the inevitable development track of the pathology. J Shandong Univ (Health Sci). 2011;49:63–6.

    CAS  Google Scholar 

  15. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8:387–98.

    Article  CAS  Google Scholar 

  16. Chan DW, Mak CS, Leung TH, Chan KK, Ngan HY. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer. Oncotarget 2012;3(Dec):1546–56.

    PubMed  PubMed Central  Google Scholar 

  17. Katoh M. Molecular cloning and characterization of human Sox17. Int J Mol Med. 2002;9:153–7.

    CAS  PubMed  Google Scholar 

  18. Venturelli S, Berger A, Weiland T, Essmann F, Waibel M, Nuebling T, et al. Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2’-deoxycytidine in solid tumor cells. Mol Cancer Ther. 2013;12(Oct):2226–36.

    Article  CAS  Google Scholar 

  19. Sajadian SO, Ehnert S, Vakilian H, Koutsouraki V, Damm G, Seehofer D, et al. Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent and suggests new treatment strategies against hepatocellular carcinoma. Clin Epigenet. 2015;11:98

    Article  Google Scholar 

  20. Zhang H, Zhou WC, Li X. 5-Azacytidine suppresses the proliferation of pancreatic cancer cells by inhibiting the Wnt/β-catenin signaling pathway. Genet Mol Res. 2014;13:5064–72.

    Article  CAS  Google Scholar 

  21. Wang Y, Zhu JF, Liu YY, Han GP. An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas. Diagn Pathol. 2013;8:8. https://doi.org/10.1186/1746-1596-8-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Liang S, Mu K, Wang Y, Zhou Z, Zhang J, Sheng Y, et al. CyclinD1, a prominent prognostic marker for endometrial diseases. Diagn Pathol. 2013;8:138

    Article  Google Scholar 

  23. Song L, Li ZY, Liu WP, Zhao MR. Crosstalk between Wnt/β-catenin and Hedgehog/Gli signaling pathways in colon cancer and implications for therapy. Cancer Biol Ther. 2015;16:1–7.

    Article  Google Scholar 

  24. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA. 2012;109:11717–22.

    Article  CAS  Google Scholar 

Download references

Funding

This work was funded by Henan Basic and Frontier Technology Research project (122300410409).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yu-Mei Liao.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liao, YM., Song, Y., Li, YK. et al. SOX17, β-catenin and CyclinD1 expression in the endometrioid adenocarcinoma and influence of 5-AZA on expression. Cancer Gene Ther 27, 256–263 (2020). https://doi.org/10.1038/s41417-019-0135-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-019-0135-5

This article is cited by

Search

Quick links